Benzydamine (BZY) is a non-steroidal anti-inflammatory drug used for the topical treatment of inflammations of the oral and vaginal mucosae. Virtually nothing is known about the central pharmacological actions of BZY. Yet there are reports of voluntary systemic overdosage of BZY in drug addicts, resulting in a euphoric, hallucinatory state. In the present study, we investigated the reinforcing properties of BZY in a rat self-administration paradigm. We found that BZY has a powerful reinforcing effect and that this effect is greatly facilitated in animals that already had substance experience, having previously self-administered heroin and cocaine, indicating cross sensitization between BZY and other common drugs of abuse. We then assessed the effect of BZY on prelimbic cortex-to-nucleus accumbens glutamatergic transmission, using field recordings in rat parasagittal brain slices. BZY dose-dependently reduced both field excitatory post synaptic potential amplitude and paired pulse ratio, suggesting a presynaptic mechanism of action. Similarly to the in vivo paradigm, also the electrophysiological effects of BZY were potentiated in slices from animals that had undergone cocaine and heroin self-administration. Furthermore, BZY-induced Long Term Depression (LTD)-like responses in the prelimbic cortex-to-nucleus accumbens circuitry were significantly reduced in the presence of the CB1 receptor antagonist AM251. These findings provide firm evidence of the abuse liability of BZY and suggest a possible cannabinoidergic mechanism of action. Further research is needed in order to give insights into the molecular mechanism underlying BZY psychoactive and reinforcing effects, to better understand its abuse potential.
Flogo-Rosa ® in Brazil). BZY is also contained in medications for systemic use (with concentrations of BZY 10 times lower than those for topical use), as in the case of Benflogin ® in Brazil, which, however, is no longer available on the market. The mechanisms of action of BZY are complex. The anti-inflammatory effect mainly depends on the inhibition of prostaglandin synthesis, probably due to disruption of calcium mobilization/sequestration at the level the plasma membrane of inflammatory cells (Jeremy et al. 1991) . BZY also exhibits a less specific mechanism of action termed 'membrane stabilization', resulting in the inhibition of granule release by neutrophils and lysosomes (Quane et al. 1998) . In addition to the anti-inflammatory/ analgesic effect, BZY has local anesthetic effects (Silvestrini et al. 1966a (Silvestrini et al. , 1966b Sato & Maehara 1967) .
Relatively little is known about the effects of BZY on the central nervous system. Symptoms such as hallucinations, dizziness and anxiety have been reported as a consequence of unintended systemic ingestion (Gómez-López et al. 1999; Ballesteros et al. 2009; Settimi et al. 2012; Acar et al. 2014) . Most important, there is evidence of recreational use of BZY in various countries, including Brazil, Italy, Poland and Turkey (Anand et al. 2007; Opaleye et al. 2009 Opaleye et al. , 2011 Settimi et al. 2012; Balaban et al. 2013; Barwina et al. 2014) . In Brazil, for example, BZY has been abused by street youth since at least the early 1990s, probably due to its low price and ready availability (Opaleye et al. 2009 ). In the following two decades, its use spread to Brazil club scene, with the blossoming of theme rave parties (Benflogin ® parties) and pop songs titled 'Benzydamine'. Informal self-reports, hosted by Internet drug forums and social networks provide information about route of administration, dosage and substance preparation from commercial preparations, as well as advice about other psychotropic substances to be assumed with BZY to enhance its pleasurable effects and dampen the undesired ones (Souza et al. 2008) . Benzydamine seems to be particularly popular among polydrug users (Anand et al. 2007; Opaleye et al. 2009 ). We have recently reported BZY use among the outpatients of an addiction clinic (Villa Maraini in Rome, Italy) with a history of heroin and cocaine co-abuse (Malavasi et al. 2012) . The major aim of the present study was to assess the reinforcing effect of BZY in animal model of drug abuse. In particular, we investigated the ability of this drug to sustain intravenous self-administration in drug-naïve rats as well as in rats that had been previously trained to selfadminister cocaine and heroin, to mimic the drug history of polydrug abusers.
The second aim of our study was to begin characterizing the neurobiological actions of BZY, as virtually nothing is known in this regard. We investigated the electrophysiological effects of BZY on prelimbic cortex-to-nucleus accumbens (PLCx-NAcc) synapses, a circuitry that is thought to play an important role in drug reward and drug seeking (Ikemoto & Panksepp 1999; Kalivas & Volkow 2005; Kalivas et al. 2009) and that has been shown to undergo neuroplastic changes following repeated drug administration (Kalivas et al. 2009; Van den Oever et al. 2012; Quintero 2013) . Interestingly, other drugs of abuse with hallucinogenic properties similar to those of BZY, such as ketamine and PCP, have been shown to reduce glutamatergic transmission (Anis et al. 1983 ). We also explored the possible involvement of CB1 receptors in the electrophysiological effects of BZY, as the chemical structure of BZY shares some features (e.g. the benzoyl indole structure) with CB1 synthetic agonists, which also have hallucinogenic properties (Forrester 2012; Harris & Brown 2013) .
MATERIALS AND METHODS

Experiment 1: Benzydamine self-administration
Animals and surgery
All the experimental procedures were carried out according the guidelines established by the European legislation (Directive 2010/63/EU) and the Italian legislation (L.D. 26/2014).
A total of 23 male Sprague-Dawley rats (Harlan Laboratories) weighting 250-300 g upon arrival were used. The rats were housed in pairs in transparent plastic cages (40 cm in length, 24.5 cm in width and 18 cm in height) with stainless steel grid tops and flat bottoms covered with ground corncob bedding, in a temperature (21 ± 1°C) and humidity (70 percent) controlled room with a 14-hour dark/10-hour light cycle (lights off at 0700 hours). The rats were gently handled twice a week for 2 weeks before undergoing surgical catheterization, following procedures described previously in detail (Caprioli et al. 2008) . On the day of surgery, the rats received an intraperitoneal injection of 2.33 mg of xylazine hydrochloride (Rompun ® , Bayer HealthCare, Berlin, Germany) and 0.56 ml/kg of Zoletil 100 ® (Virbac, Carros, France), containing tiletamine (50 mg/ml) and zolazepam (50 mg/ml). The catheter consisted of 10.5 cm of silicone tubing (0.37-mm inner diameter and 0.94-mm outer diameter) sheathed at 3.4 cm from its proximal end by a 5-mm piece of heatshrink tubing. The catheter was inserted into the right jugular vein and secured to the surrounding soft tissues with silk thread. Catheter distal end was externalized through a small incision at the nape of the neck and connected to an L-shaped 22-gauge cannula, which was secured to rat's skull using dental cement and stainless steel screws. After surgery, the rats were given 15 mg i.v. enrofloxacin (Baytril ® , KVP Pharma + Veterinär Produkte Gmbh, Kiel, Germany). The catheters were flushed daily (1800 hours) with 0.1 ml of sterile saline solution containing 0.4 mg of enrofloxacin and 25 IU heparin (Marvecs Services, Agrate Brianza, Italy). The rats had ad libitum access to food and water throughout the experiment, except during the self-administration sessions. The rats were allowed to recover from the surgery for 7-10 days and were then assigned to either the drugnaïve group (n = 12) or the drug-experienced group (n = 11) before the start of drug self-administration.
Apparatus
The apparatus (ESATEL S.r.l.; Rome, Italy) consisted of self-administration chambers (28.5-cm length, 27-cm width and 32-cm height) made of transparent plastic (front and rear walls), aluminum (sidewalls and ceiling) and stainless steel (grid floor). Plastic trays covered with pinewood shaving were placed under the cage floors. Each cage was equipped with a counterbalanced arm holding a liquid swivel and two retractable levers, positioned on the left-hand wall 12.5 cm apart and 9 cm above the floor. Cue lights consisting of either a set of triple (green, red and yellow) LED lights (in the case of heroin/cocaine self-administration) or a single white light (for BZY self-administration) were positioned above each the two levers. The self-administration cages were placed within sound-attenuating and light-attenuating cubicles. Each cage was connected via an electronic interface to a syringe pump (Razel Scientific Instruments, St. Albans, VT, USA) and to a programmable logic controller (PLC; Allen Bradley, Milwaukee, WI, USA). Finally, the PLCs were connected to PCs running control software developed by Aries Sistemi S.r.l. (Rome, Italy).
Self-administration procedures in the drug-naïve group
The rats in the drug-naïve group underwent 14 3-hour daily sessions of BZY self-administration. Independent groups (n = 4) self-administered one of three infusion doses of BZY (Sigma-Aldrich, St. Louis, MO, USA): 250, 500 and 1000 μg/kg (dissolved in 40 μl of sterile saline solution). The sessions took place during the dark phase between 0900 and 1700 hours. During the session, both levers were extended, but only one of them (counterbalanced across animals) was 'active' whereas pressing on the other lever had no scheduled consequences except resetting the counter for the active lever. The number of consecutive presses (on the active lever) required to obtain a single drug infusion (fixed ratio, FR) was progressively increased during training: FR1 on sessions 1-7, FR2 on session 8, FR3 on session 9, FR4 on session 10 and finally, FR5 on sessions 11-14. Once the appropriate FR had been reached, a drug infusion was delivered over a period of 3 seconds, and at the same time, both levers retracted for a time-out period of 40 seconds. A white cue light above the active lever was on throughout the session except during the time-out period. Rats that did not spontaneously self-administer at least one infusion within the first 5 minutes of the session were placed with their forepaws on the active lever, so as to trigger a priming infusion. Priming infusions were administered again at times 60 and 120 minutes to animals that had not spontaneously self-administered at least one infusion during time periods 5-60 and 60-120 minutes. On FR5 sessions (days 11-14), priming infusions were given only to rats that failed to self-administer at least one infusion within the 0-5-min period. These experimenter-induced lever presses were opportunely subtracted from the total. The rats were allowed to self-administer a maximum of 50 infusions within a single session.
Self-administration procedures in the drug-experienced group
The rats in the drug-experienced group were first trained to self-administer cocaine and heroin on alternate days for 12 consecutive sessions (as previously described in detail by Caprioli et al. 2009 and Montanari et al. 2015) . Briefly, during this phase, both levers were paired with cocaine and heroin in a counterbalanced manner. At the start of each session, only the lever associated with the drug to be self-administered on that session was extended, and the appropriate set of cue lights was turned on. Thus, during this phase, pressing on both levers was reinforced, and there was no 'inactive' lever. After the completion of this procedure, the rats were transferred to a different experimental room and given a 5-day period of rest. The rats were then trained to self-administer one of three infusion doses of BZY (n = 3-4), as described earlier for drug-naïve rats. Notice that the self-administration procedures for BZY differed from those for heroin and cocaine in three major ways: (1) Only one lever (either the left or the right lever, on alternate days) was extended during heroin and cocaine self-administration, whereas both levers (one 'active' and one 'inactive') were available during BZY self-administration sessions; (2) the cue lights signaling drug availability consisted of a set of triple (green, red and yellow) LED lights in the case of heroin/cocaine self-administration versus a single white light in the case of BZY self-administration; and (3) two distinct testing rooms (and related contextual cues) were used for heroin/cocaine versus BZY self-administration.
Experiment 2: Slice electrophysiology
Animals Acute brain slices were obtained from 18 drug-naïve and 5 drug-experienced male Sprague-Dawley rats of the same age of those used in the BZY self-administration experiment (P60-90 for drug-naïve rats and P80-100 for drugexperienced rats). Drug-experienced animals underwent alternate cocaine and heroin self-administration training as detailed in the previous experiment and were then given 5-7 days of rest in their home cage before being anesthetized for brain slice collection. Notice that the rats used in the electrophysiology experiments did not receive BZY self-administration training.
Slice collection
Animals were deeply anesthetized with halothane (2-bromo-2-chloro-1,1,1-trifluoroethane, Sigma-Aldrich) and decapitated. The brain was rapidly removed, and 300-μm-thick, parasagittal slices were obtained using a Leica 1200 T vibratome and immersed in a cutting solution containing (in mM): KCl 2.5, NaH 2 PO 4 1.25, MgSO 4 10, CaCl 2 0.5, Choline 120, NaHCO 3 26 and Glucose 10. The slices were then incubated in artificial cerebrospinal fluid (aCSF) in a holding chamber at 32°C for the first 60 minutes and at room temperature thereafter. Each slice was transferred to a recording chamber constantly perfused with aCSF (31-32°C, 3-4 ml/minutes) with the following composition (in mM): NaCl 126, KCl 1.25, NaH 2 PO 4 1.25, MgSO 4 2, CaCl 2 2, NaHCO 3 26 and Glucose 10. All solutions were saturated with a 95 percent O 2 to 5 percent CO 2 gas mixture.
Stimulation and recordings
Field excitatory post synaptic potentials were recorded by placing a glass recording electrode, filled with aCSF, in the core of the nucleus accumbens. Prelimbic cortical afferents were stimulated by a 25-μs square wave current delivered at 0.03 Hz (a sweep every 30 seconds) through a bipolar stainless steel microelectrode placed at the border between PLCx and NAcc. The gammaaminobutyric acid A receptor (GABA A R) antagonist picrotoxin (100 μM) was added to the perfusion aCSF because of the presence of strong GABAergic inhibition in the core of the nucleus accumbens. Signals were fed into a Multiclamp 700b amplifier (Molecular Devices, Sunnyvale, CA, USA), filtered at 1 kHz, converted by a Digidata 1322A (Molecular Devices, Sunnyvale, CA, USA), acquired and analyzed using Clampex 9.2 software.
The stimulus intensity that evoked a fEPSP of 50-60 percent of the maximal response was chosen to acquire the baseline response (15 minutes) for all experiments. For short-term plasticity experiments, a fEPSP of ∼50 percent of the maximum was obtained, and two stimuli were delivered with a 120-ms interstimulus interval. Paired pulse ratio (PPR) was calculated as fEPSP2/fEPSP1 (3 sweeps average) right before and after BZY bath perfusion. For all experiments, BZY was added at the final concentration to the perfusion aCSF. Preliminary experiments showed that at the concentration of 30 μM, BZY was effective in decreasing the PLCx-NAcc fEPSP by about 50 percent after 30 minutes of exposure, whereas at the concentration of 100 μM, fEPSP was virtually abolished. Thus, whereas in the acute perfusion experiments, the exposure time was 10 minutes (Fig. 2) , in the long-term plasticity study, the exposure time to 100 μM BZY was reduced to 8 minutes (Fig. 4) .
Data analysis and statistics
Data were analyzed using IBM SPSS 20 statistical software. In vivo data were analyzed using a four-way mixed ANOVA with between-subject factors drug experience (drug-naïve versus drug-experienced) and dose (three levels) and with repeated measures on the factor lever (active versus inactive) and session (14 levels). Electrophysiological data were analyzed using ANOVAs with repeated measures on the factor time. Data from PPR experiments were analyzed using paired samples t-test.
RESULTS
Benzydamine self-administration Figure 1 illustrates the reinforcing effects of BZY on lever pressing as a function of session and drug experience. The acquisition of BZY self-administration was greatly facilitated in drug-experienced rats relative to drug-naïve rats. Notice that drug-experienced rats readily learned to discriminate the BZY-paired lever from the 'inactive' lever even though during the cocaine/heroin training phase the rate of lever pressing on the two levers was virtually identical (see Supporting Information, Fig. S1 ). A fourway ANOVA indicated a significant main effect of lever (F 1,17 = 30.008; P < 0.001), session (F 13,221 = 8.646; P = 0.001) and drug experience (F 1,21 = 7.721; P = 0.013). There were also lever*session (F 13,221 = 10.511; P < 0.001) and lever*drug experience (F 1,21 = 5.629; P = 0.03) interactions. Furthermore, a three-way ANOVA of the number of infusions yielded a main effect of session (F 13,221 = 2.672; P = 0.014) and of drug experience (F 1,17 = 14.564; P = 0.001), as well as session*drug experience (F 13,221 = 3.183; P = 0.004) and session*training dose (F 26,221 = 2.119; P = 0.016) interactions.
Electrophysiological recordings
Bath applications of BZY at concentrations of 30 μM for 30 minutes or 100 μM BZY for 10 minutes decreased PLCx-NAcc fEPSP amplitude by 36.1 ± 6.8 percent (from 0.77 ± 0.06 to 0.51 ± 0.09 mV, n = 7) and 64.8 ± 5.7 percent (from 0.75 ± 0.07 to 0.27 ± 0.05 mV, n = 7), respectively (Fig. 2) . Repeated measures ANOVA run separately for 30 and 100-μM experimental groups on the fEPSP amplitude from the time period 15-45 showed a significant effect of time for both the 30 μM (F 60,360 = 7.954; P < 0.001) and the 100-μM concentration (F 60,360 = 18.774; P < 0.001). Furthermore, two-way repeated measures mixed ANOVA conducted on data from the time period 15-25 minutes yielded significant main effects of time (F 20,240 = 9.763; P < 0.001), concentration (F 1,12 = 25.583; P < 0.001) and a time*concentration interaction (F 20,240 = 5.253; P < 0.001). To exclude that this severe depression in synaptic transmission could be due to non-specific toxic effects of BZY, pulses of higher current intensity were delivered at the end of each experiment. Under these experimental conditions, the depressed field excitatory post synaptic potentials recovered to the baseline amplitude values (data not shown).
We also performed short-term plasticity experiments by measuring PPRs to assess if BZY-mediated effects are due to alterations of neurotransmitter release probability. In control conditions, the second synaptic response (fEPSP2) was smaller than the first (fEPSP1) (Fig. 2d) , a phenomenon termed paired pulse depression. BZY perfusion (30 μM) further decreased PPR (from 0.85 ± 0.05 baseline to 0.59 ± 0.03 after 30-minute perfusion; n = 7; t 6 = 4.978; P = 0.003), suggesting a presynaptic mechanism of drug action (Creager et al. 1980; Wu & Saggau 1994) . Because of the deep depression of the fEPSP induced by 100-μM BZY (Fig. 2f) , PPR data collected from these experiments were not included in the analyses.
The fEPSP depression induced by BZY was significantly enhanced in drug-experienced animals compared with naïve rats (Fig. 3) . Two-way mixed ANOVA for repeated measures unveiled a significant main effect of experience (F 1,21 = 9.237; P = 0.006) and experience*time interaction (F 59,1239 = 3.573; P = 0.01), indicating sensitization of PLCx-NAcc synapses to acute effects of BZY perfusion, in drugexperienced rats. Interestingly, baseline glutamatergic transmission was lower in drug-experienced rats (Fig. 3c) , as indicated by main effect of stimulus intensity (F 4,84 = 44.224, P < 0.001) and experience (F 1,21 = 11.570; P = 0.009)
As shown in Fig. 4a , bath application of 100-μM BZY for 8 minutes induced Long Term Depression (LTD) of fEPSP amplitude with a peak of À60.1 ± 5.0 percent at minutes 25-35 (from 0.55 ± 0.04 to 0.22 ± 0.03 mV; n = 9; t 8 = 9.984; P < 0.001), indicating that BZY can cause long-term changes of PLCx-NAcc synaptic connectivity. Longer time of BZY perfusion often resulted in the complete suppression of the fEPSP (Fig. 2) . The fEPSP amplitude did not fully recover during the wash out (from 0.55 ± 0.04 mV baseline to 0.36 ± 0.03 mV at time 70-80 minutes; t 8 = 6.347; P < 0.001) and was still reduced (À33.4 ± 4.5 percent) at the end of recordings. This stable LTD-like response was consistently Figure 1 Lever pressing behavior during 3-hour daily sessions of benzydamine self-administration. Fixed ratio (FR) is progressively increased throughout training. Drug-experienced animals readily acquire the self-administration behavior for all dosages, while naïve animals do so only for higher dosages. Values are displayed as means ± SEM reduced by the co-application of the CB1 receptor antagonist AM251 (F 1,19 = 18.635; P < 0.001; Fig. 4a ). In the presence of AM251 2 μM, BZY-induced fEPSP depression was smaller than in the BZY group both at the depression peak (À35.8 ± 5.7 percent versus À60.1 ± 5.0 percent; n = 12; t 19 = 3.071; P = 0.006) and at the end of recordings (À13.9 ± 3.5 percent versus À33.4 ± 4.5 percent; t 19 = 3.420; P = 0.003). Repeated measures mixed ANOVA on PPR data showed a significant time point*treatment interaction (F 2,40 = 5.548; P = 0.007). The reduction of PPR by BZY (from 0.85 ± 0.03 baseline to 0.73 ± 0.04 in the BZY group; t 8 = 2.664; P = 0.012) was fully counteracted by AM251 co-perfusion (from 0.86 ± 0.05 baseline to 0.93 ± 0.07 in the BZY + AM251 group; t 11 = 1.577; P = 0.143; Fig. 4b ). AM251 did not affect PPR per se (0.93 ± 0.06, P = 0.175 versus baseline PPR, data not shown). Consistent with these results during the perfusion of the CB1 agonist WIN 55,212-2 (1 μM), the amount of fEPSP depression produced by BZY was smaller by 62.8 ± 4.7 percent than that produced by BZY alone (n = 10, Fig. 4c ), thus suggesting that BZY and WIN 55,212-2 share a common pathway. Taken together, these data indicate that the effects of BZY on glutamatergic neurotransmission are likely mediated by cannabinoid mechanisms.
DISCUSSION
We report here three major novel findings. First, we found that BZY, a non-steroidal anti-inflammatory drug, is selfadministered intravenously by rats and that the reinforcing effects of BZY are greatly enhanced by a history of heroin and cocaine self-administration. Second, we found that BZY induces LTD-like plasticity at PLCx-NAcc synapses. Third, we found that this latter effect was significantly reduced by the CB1 receptor antagonist AM251, suggesting a cannabinoidergic mechanism of action.
Benzydamine abuse is well documented in Brazil (Opaleye et al. 2009 (Opaleye et al. , 2011 and other countries, including Italy (Malavasi et al. 2012; Settimi et al. 2012) , Poland (Anand et al. 2007) and Turkey (Balaban et al. 2013) . The finding that BZY is reinforcing in the rat sheds a light on two aspects of BZY abuse in humans. The first aspect concerns its addictive potential. There is little information on the subjective effects of BZY in the scientific literature, except for its hallucinogenic effects (Opaleye et al. 2009 ). Yet hallucinogenic substances, such as LSD, mescaline and DOM, have relatively little addictive potential in humans (Nutt et al. 2007) , and there is little or no evidence of self-administration of in rodents (Deneau et al. 1969; Yanagita 1986 ). However, informal subjective reports posted in drug forums indicate that BZY has both stimulant and hallucinogenic properties. Substances with mixed hallucinogenic and psychostimulant effects, such as MDMA or ketamine, have greater abuse potential than purely hallucinogenic drugs and are self-administered by monkeys (Lamb & Griffiths 1987; Fantegrossi et al. 2002) and rats (Ratzenboeck et al. 2001; Schenk et al. 2003; De Luca & Badiani 2011; De Luca et al. 2012) . In summary, the reinforcing effects of BZY described here in the rat are consistent with the stimulant and hallucinogenic effects reported in drug forums.
The second important aspect of BZY abuse is that most cases concern individuals with a history of drug addiction and polydrug use (Anand et al. 2007; Opaleye et al. 2009; Malavasi et al. 2012) , suggesting that the reinforcing effects of BZY are facilitated by previous drug exposure. Indeed, in the present study, we found that although BZY acted as a positive reinforcer in both naïve rats and in rats with a history of cocaine and heroin self-administration, the latter acquired BZY selfadministration at a very low unit dose, which was not effective in naïve rats.
The mechanism underlying the reinforcing effects of BZY is unknown. Actually, to the best of our knowledge, this is the first study reporting on the neurobiological effects of BZY. We have shown that BZY can produce short-term and long-term changes in excitatory synaptic transmission in the PLCx-NAcc circuitry. In particular, acute BZY reduced PLCx-NAcc glutamatergic transmission via a presynaptic mechanism. The depressive effect of BZY on glutamatergic transmission was greater, similar to its reinforcing effect, in rats that had previously self-administered cocaine and heroin than in naïve rats. This phenomenon might be related to differences in baseline PLCx-NAcc glutamatergic transmission as indicated by the input-output curves for the two groups (Fig. 3) or to alterations of cannabinoid signaling between drug-experienced and drug-naïve animals (Rivera et al. 2013) . Interestingly, previous studies have shown that cocaine and damphetamine can depress excitatory neurotransmission at PLCx-NAcc synapses via dopamine DA1 receptors (Nicola et al. 1996) . However, BZY-induced LTD does not appear to depend on dopaminergic mechanisms because it was not affected by the selective D1 antagonist SCH23390 (data not shown).
In contrast, the BZY-induced LTD of glutamatergic transmission seems to depend at least in part on the presence of CB1 receptors on glutamatergic presynaptic terminals. The CB1R antagonist AM251 reduced in fact BZY-induced LTD as well as BZY-induced changes in PPR. Interestingly, amphetamine has been found to induce CB1-dependent LTD in the rat amygdala (Huang et al. 2003) . The mechanism by which BZY interacts with CB1 receptors remains unclear. BZY might act as a direct agonist at CB1 receptors. Activation of CB1 receptors by WIN 55,212-2 has been shown in fact to induce persistent and long lasting fEPSP LTD in the NAcc (Robbe et al. 2002) . Consistent with this hypothesis, occlusion experiments the CB1 receptor agonist WIN corroborated that the partial inhibition of BZY by AM251 was due to the involvement of CB1 receptors (Fig. 4) . Alternatively, BZY might influence endocannabinoid synthesis and release (Löffler et al. 1987) , which in turn regulates glutamatergic transmission (Domenici et al. 2006) . Of course, given that AM251 dampened but not abolished BZY-induced LTD, it is not possible to exclude the contribution of other neurotransmitter systems.
The critical role of CB1R in modulating BZY-induced synaptic plasticity provides a potential mechanism for the abuse potential of BZY. Interestingly, the chemical structure of BZY shares some features (like the presence of a benzoyl indole) with several CB1 synthetic agonists (i.e. the JWH series compounds), which have been shown to possess hallucinogenic properties (Forrester 2012; Harris & Brown 2013) . Future self-administration studies utilizing CB1 antagonists will be necessary to fully elucidate the degree to which CB1 receptors are involved in the reinforcing effects of BZY.
In conclusion, we provide here the first empirical evidence of the reinforcing effects of BZY and of its ability to produce short-term and long-term changes in glutamatergic transmission in PLCx-NAcc synapses (a circuitry implicated in drug reward), possibly mediated by a cannabinoidergic mechanism of action. Further research is needed in order to better characterize these neurophysiological effects of BZY. Our findings also suggest that individuals with a history of substance abuse might be more prone to develop BZY abuse not only as a consequence of a general predisposition to experiment with psychoactive substances but also because of a specific pharmacological cross-sensitization to its reinforcing effects. This could be of particular relevance for the management of detention facilities or rehabilitation clinics, considering that an addict might consume BZY (or similar substances) as a substitute drug without even being noticed by supervisors, thus unpredictably compromising health conditions along with therapy efficacy.
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